blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2651410

EP2651410 - TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTERING AN ACTIVE SUBSTANCE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  20.08.2021
Database last updated on 24.08.2024
FormerThe patent has been granted
Status updated on  11.09.2020
FormerGrant of patent is intended
Status updated on  05.05.2020
FormerExamination is in progress
Status updated on  28.07.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Luye Pharma AG
Am Windfeld 35
83714 Miesbach / DE
[2017/12]
Former [2013/43]For all designated states
Acino AG
Am Windfeld 35
83714 Miesbach / DE
Inventor(s)01 / LANGER, Britta
Alte Brauerei 12
10965 Berlin / DE
02 / SCHURAD, Bjoern
Michael-Huber-Weg 26
81667 München / DE
03 / PRINZ, Heike
Malvenweg 16
82008 Unterhaching / DE
 [2013/43]
Representative(s)Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
[N/P]
Former [2020/42]Kalhammer, Georg, et al
Lederer & Keller
Patentanwälte Partnerschaft mbB
Unsöldstrasse 2
80538 München / DE
Former [2013/43]Kalhammer, Georg, et al
Lederer & Keller Patentanwälte Unsöldstrasse 2
80538 München / DE
Application number, filing date11799413.714.12.2011
[2020/42]
WO2011EP72812
Priority number, dateEP2010019496814.12.2010         Original published format: EP 10194968
[2013/43]
Filing languageDE
Procedural languageDE
PublicationType: A1 Application with search report
No.:WO2012080365
Date:21.06.2012
Language:DE
[2012/25]
Type: A1 Application with search report 
No.:EP2651410
Date:23.10.2013
Language:DE
The application published by WIPO in one of the EPO official languages on 21.06.2012 takes the place of the publication of the European patent application.
[2013/43]
Type: B1 Patent specification 
No.:EP2651410
Date:14.10.2020
Language:DE
[2020/42]
Search report(s)International search report - published on:EP21.06.2012
ClassificationIPC:A61K9/70, A61K31/27, A61P17/00, A61P25/16, A61P25/28
[2020/21]
CPC:
A61K9/7084 (EP,CN,US); A61K9/70 (KR); A61K31/27 (EP,CN,KR,US);
A61K47/32 (CN); A61P17/00 (EP); A61P25/16 (EP);
A61P25/28 (EP) (-)
Former IPC [2013/43]A61K31/27, A61K9/00, A61K9/70
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/43]
Extension statesBA12.07.2013
ME12.07.2013
TitleGerman:TRANSDERMALES THERAPEUTISCHES SYSTEM ZUR VERABREICHUNG EINES WIRKSTOFFS[2013/43]
English:TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTERING AN ACTIVE SUBSTANCE[2013/43]
French:SYSTÈME THÉRAPEUTIQUE TRANSDERMIQUE POUR L'ADMINISTRATION D'UN PRINCIPE ACTIF[2013/43]
Entry into regional phase05.07.2013National basic fee paid 
05.07.2013Designation fee(s) paid 
05.07.2013Examination fee paid 
Examination procedure05.07.2013Examination requested  [2013/43]
14.02.2014Amendment by applicant (claims and/or description)
28.07.2017Despatch of a communication from the examining division (Time limit: M06)
06.02.2018Reply to a communication from the examining division
03.07.2019Despatch of a communication from the examining division (Time limit: M04)
13.11.2019Reply to a communication from the examining division
06.05.2020Communication of intention to grant the patent
31.08.2020Fee for grant paid
31.08.2020Fee for publishing/printing paid
31.08.2020Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  28.07.2017
Opposition(s)15.07.2021No opposition filed within time limit [2021/38]
Fees paidRenewal fee
23.12.2013Renewal fee patent year 03
18.12.2014Renewal fee patent year 04
26.11.2015Renewal fee patent year 05
24.11.2016Renewal fee patent year 06
07.11.2017Renewal fee patent year 07
27.11.2018Renewal fee patent year 08
21.11.2019Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL14.10.2020
MK14.10.2020
[2022/32]
Former [2021/45]AL14.10.2020
Cited inInternational search[XDI]DE19918106  (LOHMANN THERAPIE SYST LTS [DE]) [XD] 56-61 * page 2, line 3 - page 3, line 37 * * page 4, line 7 - page 5, line 65 * * claims 1, 2, 5, 6, 24, 26 * * figure 5 * [I] 1-16,31,47-61;
 [AD]WO2007064407  (NOVARTIS AG [CH], et al) [AD] 1-61 * page 1, paragraph 1 - page 3, paragraph 5 * * page 6, paragraph 1 - paragraph 4 * * page 7, paragraph 4 - paragraph 5 * * page 8, paragraph 4 - page 9, paragraph 1 * * example I. * * claims 1, 3, 9-11, 15, 20 *;
 [XI]US2008175890  (YUM SU IL [US], et al) [X] 17,18,22-30,47,48,50-55 * page 10, paragraph 0077 - page 11, paragraph 0083 * * page 12, paragraphs 0089-0092 * * page 14, paragraph 0101 - page 15, paragraph 0111 * * figure 2 * * claim - * [I] 19;
 [XI]WO2009009651  (AGILE THERAPEUTICS INC [US], et al) [X] 17-19,22-30,47-49 * page 2, lines 17-30 * * page 4, line 19 - page 5, line 3 * * page 5, line 24 - page 6, line 15 * * page 9, line 19 - page 10, line 15 * * figure - *[I] 50-55;
 [XDI]EP2016939  (TEIKOKU SEIYAKU KK [JP]) [XD] 1,3-5,9,14-16,32-58,60 * page 1, paragraph 0002 * * page 3, paragraph 0013 - paragraph 0015 * * page 3, paragraph 0016; figure 2 * * page 3, paragraph 0018 - page 5, paragraph 0041 * * page 7, paragraph 0064 - page 8, paragraph 0075 * * claims 1, 3, 6 * [I] 1-16,31,41-61;
 [XI]WO2009026135  (ALZA CORP [US], et al) [X] 17-19,21-23,25-30,50-55 * page 5, paragraph 00013 - page 6, paragraph 00014 * * page 11, paragraph 00039 - page 13, paragraph 00043 * * page 15, paragraph 00047 - page 17, paragraph 00053 * * page 25, paragraphs 00069-00070 * * example 2 * * figures 1-2 * [I] 20
by applicantGB2203040
 DE19918106
 EP1047409
 WO0203969
 WO03017988
 US6689379
 US2004086552
 WO2007064407
 US2007259028
 WO2008021113
 US2008044461
 EP2016939
    - "OECD GUIDELINE FOR THE TESTING OF CHEMICALS. Skin Absorption: in vitro method.", TEST GUIDELINE, (20040413), vol. 428, pages 1 - 8
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.